Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis.
Chaudhary R, Singh A, Chaudhary R, Bashline M, Houghton DE, Rabinstein A, Adamski J, Arndt R, Ou NN, Rudis MI, Brown CS, Wieruszewski ED, Wanek M, Brinkman NJ, Linderbaum JA, Sorenson MA, Atkinson JL, Thompson KM, Aiyer AN, McBane RD 2nd. Chaudhary R, et al. Among authors: arndt r. JAMA Netw Open. 2022 Nov 1;5(11):e2240145. doi: 10.1001/jamanetworkopen.2022.40145. JAMA Netw Open. 2022. PMID: 36331504 Free PMC article.
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
Ganesh R, Philpot LM, Bierle DM, Anderson RJ, Arndt LL, Arndt RF, Culbertson TL, Destro Borgen MJ, Hanson SN, Kennedy BD, Kottke BB, Larsen JJ, Ramar P, Rosedahl JK, Seville MT, Speicher LL, Tulledge-Scheitel SM, Wilker CG, Razonable RR. Ganesh R, et al. Among authors: arndt ll, arndt rf. J Infect Dis. 2021 Oct 28;224(8):1278-1286. doi: 10.1093/infdis/jiab377. J Infect Dis. 2021. PMID: 34279629 Free PMC article.
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
Ganesh R, Pawlowski CF, O'Horo JC, Arndt LL, Arndt RF, Bell SJ, Bierle DM, Borgen MD, Hanson SN, Heyliger A, Larsen JJ, Lenehan PJ, Orenstein R, Puranik A, Speicher LL, Tulledge-Scheitel SM, Venkatakrishnan AJ, Wilker CG, Badley AD, Razonable RR. Ganesh R, et al. Among authors: arndt ll, arndt rf. J Clin Invest. 2021 Oct 1;131(19):e151697. doi: 10.1172/JCI151697. J Clin Invest. 2021. PMID: 34411003 Free PMC article.
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.
Razonable RR, O'Horo JC, Hanson SN, Arndt RF, Speicher LL, Seville TA, Hall ST, Pike ML, Heyliger A, Larsen JJ, Ganesh R, Tulledge-Scheitel SM. Razonable RR, et al. Among authors: arndt rf. J Infect Dis. 2022 Nov 11;226(10):1683-1687. doi: 10.1093/infdis/jiac346. J Infect Dis. 2022. PMID: 36124696 Free PMC article.
Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.
Razonable RR, Tulledge-Scheitel SM, Hanson SN, Arndt RF, Speicher LL, Seville TA, Larsen JJ, Ganesh R, O'Horo JC. Razonable RR, et al. Among authors: arndt rf. Open Forum Infect Dis. 2022 Oct 6;9(10):ofac411. doi: 10.1093/ofid/ofac411. eCollection 2022 Oct. Open Forum Infect Dis. 2022. PMID: 36213724 Free PMC article.
Clinical outcomes of COVID-19 treated with remdesivir across the continuum of care.
Rivera CG, Chesdachai S, Draper EW, Arndt RF, Mara KC, Gonzalez Suarez M, Razonable RR. Rivera CG, et al. Among authors: arndt rf. Influenza Other Respir Viruses. 2023 May 17;17(5):e13136. doi: 10.1111/irv.13136. eCollection 2023 May. Influenza Other Respir Viruses. 2023. PMID: 37228805 Free PMC article.
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.
Razonable RR, Pawlowski C, O'Horo JC, Arndt LL, Arndt R, Bierle DM, Borgen MD, Hanson SN, Hedin MC, Lenehan P, Puranik A, Seville MT, Speicher LL, Tulledge-Scheitel SM, Venkatakrishnan AJ, Wilker CG, Badley AD, Ganesh R. Razonable RR, et al. Among authors: arndt ll, arndt r. EClinicalMedicine. 2021 Oct;40:101102. doi: 10.1016/j.eclinm.2021.101102. Epub 2021 Aug 30. EClinicalMedicine. 2021. PMID: 34485873 Free PMC article.
Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant.
O'Horo JC, Challener DW, Speicher L, Bosch W, Seville MT, Bierle DM, Ganesh R, Wilker CG, Arndt RF, Arndt LL, Tulledge-Scheitel SM, Hanson SN, Razonable RR. O'Horo JC, et al. Among authors: arndt ll, arndt rf. Mayo Clin Proc. 2022 Feb;97(2):327-332. doi: 10.1016/j.mayocp.2021.12.002. Epub 2021 Dec 16. Mayo Clin Proc. 2022. PMID: 35120695 Free PMC article.
Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
O'Horo J, Challener DW, Anderson RJ, Arndt RF, Ausman SE, Hall ST, Heyliger A, Kennedy BD, Sweeten PW, Ganesh R, Razonable RR. O'Horo J, et al. Among authors: arndt rf. Mayo Clin Proc. 2022 May;97(5):943-950. doi: 10.1016/j.mayocp.2022.02.009. Epub 2022 Feb 23. Mayo Clin Proc. 2022. PMID: 35512884 Free PMC article.
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR, O'Horo JC, Challener DW, Arndt L, Arndt RF, Clune CG, Culbertson TL, Hall ST, Heyliger A, Jackson TA, Kennedy BD, Larsen J, Hanson SN, Sweeten PW, Tulledge-Scheitel SM, Ganesh R. Razonable RR, et al. Among authors: arndt rf, arndt l. Mayo Clin Proc. 2022 Sep;97(9):1641-1648. doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23. Mayo Clin Proc. 2022. PMID: 36058578 Free PMC article.
291 results